Niquitin Minilozenge (Nicotine)

The nicotine in the lozenge acts as an agonist at nicotinic acetylcholine receptors in the brain, especially the α4β2 subtype. By providing a low, steady nicotine stimulus, it mimics the effect of tobacco smoke, which lessens the severity of withdrawal and helps the user gradually taper nicotine intake.

The specific dose and duration are determined by a qualified healthcare professional based on the individual’s smoking history, level of dependence, and overall health. Prescribers follow established clinical guidelines to select the appropriate lozenge strength and treatment length for each patient.

Safety data for nicotine lozenges in pregnancy and lactation are limited, and the product’s pregnancy category is listed as unknown. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using the lozenge.

To place an enquiry, visit the product page on gnhindia.com and submit the required quantity details. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping options and any necessary import documentation.

Compared with nicotine gum or transdermal patches, the lozenge provides a rapid, controllable dose that is absorbed through the oral mucosa. This can be advantageous for users who prefer discreet, on‑the‑go dosing. However, individual preferences, side‑effect profiles and treatment goals determine the most suitable nicotine replacement form.

Store the lozenges at ambient temperature, preferably below 25 °C, in their original packaging. Keep them away from moisture, direct sunlight and heat sources. Ensure the container is tightly closed to maintain product stability and keep it out of reach of children.

The lozenge should be placed in the mouth and allowed to dissolve slowly, moving it occasionally from one side of the mouth to the other. Do not chew or swallow the lozenge whole. Avoid eating or drinking for at least 15 minutes after the lozenge has fully dissolved.

Serious risks, although rare, include cardiovascular events such as chest pain or arrhythmias, and severe allergic reactions like anaphylaxis. Users should seek immediate medical attention if they experience any signs of a serious reaction, especially chest discomfort, difficulty breathing, or swelling of the face and throat.

The lozenge is contraindicated for non‑smokers, children, and individuals with known hypersensitivity to nicotine or any excipients in the product. Patients with uncontrolled cardiovascular disease should use it only under close medical supervision, and those with recent myocardial infarction should discuss suitability with their physician.